Category:

18 November 2024

FIRST SIGNIFICANT SALES RESULTS IN CHINA

11 November 2024

PHARMANUTRA S.P.A.: THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT SEPTEMBER 30, 2024

04 November 2024

PHARMANUTRA S.P.A. APPLIES ITS PROPRIETARY SUCROSOMIAL® TECHNOLOGY TO VITAMINS AND LAUNCHES NEW SIDEVIT® LINE

29 October 2024

AGREEMENT WITH AN INTERNATIONAL ADVISOR IN ORDER TO DEFINE A DEVELOPMENT PLAN FOR PHARMANUTRA USA

02 October 2024

ALLEGATO 3F – SETTEMBRE 2024

09 September 2024

BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2024

03 September 2024

ALLEGATO 3F – AGOSTO 2024

03 September 2024

LAUNCH OF TWO SIDERAL® PRODUCTS IN GERMANY

01 August 2024

ALLEGATO 3F – LUGLIO 2024

24 July 2024

Significant Sales and Market Positioning Results in the Italian Nutraceutical Market

08 July 2024

Allegato 3F Giugno 2024

05 July 2024

Effectiveness of the merger by incorporation

22 June 2024

Internal dealing communication

18 June 2024

THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO

13 June 2024

A NEW STUDY HIGHLIGHTS THE EFFICACY, SUPERIORITY AND IMPROVED TOLERABILITY OF SIDERAL® COMPARED TO CONVENTIONAL IRON SUPPLEMENT TREATMENTS

12 June 2024

INITIATION OF SHARE BUY-BACK PROGRAM

29 May 2024

ASSUNZIONE QUALIFICA DI PMI

13 May 2024

PHARMANUTRA S.P.A. THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT 31 MARCH2024 AND THE 2023 SUSTAINABILITY REPORT

15 April 2024

THE MERGER BY INCORPORATION INTO PHARMANUTRA S.P.A. OF JUNIA PHARMA S.R.L. AND ALESCO S.R.L. HAS BEEN APPROVED

15 March 2024

PHARMANUTRA S.P.A.: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2023

26 February 2024

Approval of the merger plan

1 2 … 11 >